Advanced Accelerator Preps Lutetium-Tipped Warhead For NETs Filings
This article was originally published in The Pink Sheet Daily
France’s Advanced Accelerator Applications is making plans to extend its business to the US after its lead radiotherapeutic, a lutetium labelled somatostatin analog, met its primary endpoint in a Phase III study.
You may also be interested in...
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.